DEC TIMOTHY C
Insider CIK 1194020 · OPGN,OPGNW Chief Financial Officer · FIGI Chief Financial Officer · SUPN Senior Vice-President & CFO
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-10-30 | 2026-11-02 | 70,000 | — | $0 | 70,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-08-12 | 2026-08-14 | 1,250 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-08-12 | 2026-08-14 | 604 | $46.57 | $28.1K | 9,129 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-08-12 | 2026-08-14 | 1,250 | — | $0 | 9,733 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-08-12 | 2026-08-14 | 1,250 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-08-12 | 2026-08-14 | 604 | $46.57 | $28.1K | 9,129 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-08-12 | 2026-08-14 | 1,250 | — | $0 | 9,733 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-07-29 | 2026-07-31 | 1,250 | — | $0 | 1,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-07-29 | 2026-07-31 | 1,250 | — | $0 | 1,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-03-06 | 2026-03-10 | 3,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-03-06 | 2026-03-10 | 3,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-03-06 | 2026-03-10 | 3,000 | — | $0 | 8,115 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-03-06 | 2026-03-10 | 1,433 | $54.73 | $78.4K | 6,682 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-03-06 | 2026-03-10 | 3,000 | — | $0 | 9,682 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-03-06 | 2026-03-10 | 1,450 | $54.73 | $79.4K | 8,232 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-02-28 | 2026-03-03 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-02-28 | 2026-03-03 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-25 | 2026-02-26 | 2,500 | — | $0 | 2,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-25 | 2026-02-26 | 1,279 | $50.69 | $64.8K | 5,115 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-25 | 2026-02-26 | 2,500 | — | $0 | 6,394 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-24 | 2026-02-25 | 500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-24 | 2026-02-25 | 3,000 | — | $0 | 6,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-24 | 2026-02-25 | 1,125 | — | $0 | 3,375 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-24 | 2026-02-25 | 242 | $50.86 | $12.3K | 2,418 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-24 | 2026-02-25 | 603 | $51.35 | $31.0K | 2,160 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-24 | 2026-02-25 | 1,125 | — | $0 | 2,763 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-24 | 2026-02-25 | 3,000 | — | $0 | 5,418 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-24 | 2026-02-25 | 1,524 | $50.86 | $77.5K | 3,894 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-24 | 2026-02-25 | 500 | — | $0 | 2,660 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-02-18 | 2026-02-20 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-02-18 | 2026-02-20 | 17,500 | — | $0 | 17,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-08-22 | 2025-08-26 | 11,780 | $44.49 | $524.1K | 1,246 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-03-10 | 2025-03-11 | 1,800 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-03-10 | 2025-03-11 | 2,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-03-10 | 2025-03-11 | 1,800 | — | $0 | 13,636 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-03-10 | 2025-03-11 | 2,000 | — | $0 | 12,898 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-10 | 2025-03-11 | 955 | $32.06 | $30.6K | 12,681 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-10 | 2025-03-11 | 1,062 | $32.06 | $34.0K | 11,836 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-05 | 2025-03-05 | 1,587 | $33.05 | $52.5K | 12,228 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-05 | 2025-03-05 | 1,330 | $33.05 | $44.0K | 10,898 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-05 | 2025-03-05 | 276 | $33.05 | $9.1K | 13,815 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-28 | 2025-03-04 | 1,800 | — | $0 | 1,800 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-28 | 2025-03-04 | 2,000 | — | $0 | 2,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2025-02-23 | 2025-02-24 | 2,500 | — | $0 | 5,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2025-02-23 | 2025-02-24 | 2,500 | — | $0 | 14,091 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2025-02-22 | 2025-02-24 | 3,000 | — | $0 | 9,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2025-02-22 | 2025-02-24 | 500 | — | $0 | 500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2025-02-22 | 2025-02-24 | 3,000 | — | $0 | 11,591 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2025-02-22 | 2025-02-24 | 500 | — | $0 | 8,591 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-19 | 2025-02-21 | 40,000 | — | $0 | 40,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-19 | 2025-02-21 | 4,500 | — | $0 | 4,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2024-02-23 | 2024-02-27 | 2,500 | — | $0 | 7,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2024-02-23 | 2024-02-27 | 2,500 | — | $0 | 8,504 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-02-23 | 2024-02-27 | 1,314 | $29.06 | $38.2K | 7,190 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-02-22 | 2024-02-26 | 50,000 | — | $0 | 50,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-02-22 | 2024-02-26 | 12,000 | — | $0 | 12,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2024-02-22 | 2024-02-26 | 500 | — | $0 | 1,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2024-02-22 | 2024-02-26 | 500 | — | $0 | 6,004 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-10-13 | 2023-10-13 | 4,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2023-10-13 | 2023-10-13 | 1,911 | $26.91 | $51.4K | 5,089 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-10-13 | 2023-10-13 | 4,000 | — | $0 | 7,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-10-04 | 2023-10-06 | 4,000 | — | $0 | 4,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-05-11 | 2023-05-12 | 1,500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2023-05-11 | 2023-05-12 | 709 | $36.47 | $25.9K | 2,650 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-05-11 | 2023-05-12 | 1,500 | — | $0 | 3,359 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-05-04 | 2023-05-08 | 1,500 | — | $0 | 1,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-03-14 | 2023-04-10 | 1,500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2023-03-14 | 2023-04-10 | 789 | $38.65 | $30.5K | 2,052 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-03-14 | 2023-04-10 | 1,500 | — | $0 | 2,841 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-23 | 2023-02-27 | 10,000 | — | $0 | 10,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-23 | 2023-02-27 | 40,000 | — | $0 | 40,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2023-02-22 | 2023-04-12 | 500 | — | $0 | 1,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2023-02-22 | 2023-04-12 | 193 | $38.57 | $7.4K | 1,148 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2023-02-22 | 2023-04-12 | 500 | — | $0 | 1,341 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2023-02-22 | 2023-02-24 | 500 | — | $0 | 1,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2023-02-22 | 2023-02-24 | 500 | — | $0 | 1,341 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-16 | 2023-02-21 | 1,500 | — | $0 | 1,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-24 | 2,000 | — | $0 | 2,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-24 | 25,000 | — | $0 | 25,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-25 | 25,000 | — | $0 | 25,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-25 | 2,000 | — | $0 | 2,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2021-08-23 | 2021-08-24 | 85,000 | — | $0 | 85,000 | SEC↗ |
| OPGN OPGEN INC | M Exercise deriv | 2021-05-17 | 2021-05-19 | 583 | — | $0 | 584 | SEC↗ |
| OPGN OPGEN INC | M Exercise | 2021-05-17 | 2021-05-19 | 583 | — | $0 | 1,509 | SEC↗ |
| OPGN OPGEN INC | A Award deriv | 2021-03-03 | 2021-03-05 | 42,500 | — | $0 | 42,500 | SEC↗ |
| OPGN OPGEN INC | A Award deriv | 2021-03-03 | 2021-03-05 | 42,500 | — | $0 | 42,500 | SEC↗ |
| OPGN OPGEN INC | A Award deriv | 2020-09-30 | 2020-10-02 | 210,000 | — | $0 | 210,000 | SEC↗ |
| OPGN OPGEN INC | M Exercise deriv | 2020-05-17 | 2020-05-19 | 583 | — | $0 | 1,167 | SEC↗ |
| OPGN OPGEN INC | M Exercise | 2020-05-17 | 2020-05-19 | 583 | — | $0 | 926 | SEC↗ |
| OPGN OPGEN INC | M Exercise deriv | 2019-11-10 | 2019-11-12 | 12 | — | $0 | 0 | SEC↗ |
| OPGN OPGEN INC | M Exercise | 2019-11-10 | 2019-11-12 | 12 | — | $0 | 345 | SEC↗ |
| OPGN OPGEN INC | A Award deriv | 2019-05-17 | 2019-05-20 | 35,000 | — | $0 | 35,000 | SEC↗ |
| OPGN OPGEN INC | M Exercise deriv | 2018-02-23 | 2018-02-27 | 1,400 | — | $0 | 0 | SEC↗ |
| OPGN OPGEN INC | M Exercise | 2018-02-23 | 2018-02-27 | 1,400 | — | $0 | 6,408 | SEC↗ |
| OPGN OPGEN INC | A Award deriv | 2018-01-23 | 2018-01-25 | 12,000 | — | $0 | 12,000 | SEC↗ |
| OPGN OPGEN INC | M Exercise deriv | 2017-11-10 | 2017-11-14 | 6,250 | — | $0 | 12,500 | SEC↗ |
| OPGN OPGEN INC | M Exercise | 2017-11-10 | 2017-11-14 | 6,250 | — | $0 | 125,216 | SEC↗ |
| OPGN OPGEN INC | A Award deriv | 2017-08-09 | 2017-08-11 | 60,000 | — | $0 | 60,000 | SEC↗ |
| OPGN OPGEN INC | A Award deriv | 2017-08-09 | 2017-08-11 | 35,000 | — | $0 | 35,000 | SEC↗ |
| OPGN OPGEN INC | A Award deriv | 2017-07-18 | 2017-07-18 | 65,000 | — | $0 | 65,000 | SEC↗ |
| OPGN OPGEN INC | P Buy | 2017-07-18 | 2017-07-18 | 65,000 | $0.40 | $26.0K | 118,966 | SEC↗ |
| OPGN OPGEN INC | A Award deriv | 2017-02-23 | 2017-02-27 | 68,000 | — | $0 | 68,000 | SEC↗ |
| OPGN OPGEN INC | A Award deriv | 2016-06-13 | 2016-06-14 | 60,000 | — | $0 | 60,000 | SEC↗ |
| OPGN OPGEN INC | P Buy deriv | 2016-05-19 | 2016-05-23 | 43,716 | — | $0 | 43,716 | SEC↗ |
| OPGN OPGEN INC | P Buy | 2016-05-19 | 2016-05-23 | 43,716 | — | $0 | 47,716 | SEC↗ |
| OPGN OPGEN INC | A Award deriv | 2015-11-10 | 2015-11-12 | 50,000 | — | $0 | 50,000 | SEC↗ |
| OPGN OPGEN INC | A Award deriv | 2015-11-10 | 2015-11-12 | 25,000 | — | $0 | 25,000 | SEC↗ |
| OPGN,OPGNW OPGEN INC | P Buy deriv | 2015-05-08 | 2015-05-12 | 4,000 | — | $0 | 4,000 | SEC↗ |
| OPGN,OPGNW OPGEN INC | P Buy | 2015-05-08 | 2015-05-12 | 4,000 | $6.00 | $24.0K | 4,000 | SEC↗ |
| OPGN,OPGNW OPGEN INC | A Award deriv | 2015-05-04 | 2015-05-06 | 114,320 | — | $0 | 114,320 | SEC↗ |
| FIGI.PK Fortress International Gro | A Award deriv | 2012-06-06 | 2012-06-08 | 150,000 | — | $0 | 150,000 | SEC↗ |
| FIGI Fortress International Gro | F Tax w/h | 2012-01-03 | 2012-01-04 | 8,180 | $0.88 | $7.2K | 285,005 | SEC↗ |